A morphologic variant of schwannoma characterized by hypercellularity, Antoni A pattern, and the absence of well-formed Verocay bodies.
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation for cellular schwannoma is limited primarily due to its rarity, affecting fewer than a few hundred individuals worldwide. This rarity makes systematic clinical studies challenging, resulting in insufficient data on genetic factors and clinical features. Ongoing research may provide more insights in the future.
To navigate your care for cellular schwannoma, seek out a specialist in neuro-oncology or a surgeon with experience in treating schwannomas. While there are currently no identified patient organizations, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for additional support. Participation in clinical trials may also be an option; check the active trials listed on ClinicalTrials.gov for opportunities.
Currently, there is one orphan drug designated for cellular schwannoma: Live attenuated Salmonella enterica Serovar Typhimurium (S. Typhimurium). Additionally, there are 39 active clinical trials exploring various aspects of this condition. You can find more information about these trials at ClinicalTrials.gov by searching for 'cellular schwannoma'.
Actionable guidance for navigating care for cellular schwannoma
To navigate your care for cellular schwannoma, seek out a specialist in neuro-oncology or a surgeon with experience in treating schwannomas. While there are currently no identified patient organizations, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for additional support. Participation in clinical trials may also be an option; check the active trials listed on ClinicalTrials.gov for opportunities.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for cellular schwannoma is limited primarily due to its rarity, affecting fewer than a few hundred individuals worldwide. This rarity makes systematic clinical studies challenging, resulting in insufficient data on genetic factors and clinical features. Ongoing research may provide more insights in the future.
To navigate your care for cellular schwannoma, seek out a specialist in neuro-oncology or a surgeon with experience in treating schwannomas. While there are currently no identified patient organizations, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for additional support. Participation in clinical trials may also be an option; check the active trials listed on ClinicalTrials.gov for opportunities.
Currently, there is one orphan drug designated for cellular schwannoma: Live attenuated Salmonella enterica Serovar Typhimurium (S. Typhimurium). Additionally, there are 39 active clinical trials exploring various aspects of this condition. You can find more information about these trials at ClinicalTrials.gov by searching for 'cellular schwannoma'.
Actionable guidance for navigating care for cellular schwannoma
To navigate your care for cellular schwannoma, seek out a specialist in neuro-oncology or a surgeon with experience in treating schwannomas. While there are currently no identified patient organizations, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for additional support. Participation in clinical trials may also be an option; check the active trials listed on ClinicalTrials.gov for opportunities.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for cellular schwannoma is limited primarily due to its rarity, affecting fewer than a few hundred individuals worldwide. This rarity makes systematic clinical studies challenging, resulting in insufficient data on genetic factors and clinical features. Ongoing research may provide more insights in the future.
To navigate your care for cellular schwannoma, seek out a specialist in neuro-oncology or a surgeon with experience in treating schwannomas. While there are currently no identified patient organizations, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for additional support. Participation in clinical trials may also be an option; check the active trials listed on ClinicalTrials.gov for opportunities.
Currently, there is one orphan drug designated for cellular schwannoma: Live attenuated Salmonella enterica Serovar Typhimurium (S. Typhimurium). Additionally, there are 39 active clinical trials exploring various aspects of this condition. You can find more information about these trials at ClinicalTrials.gov by searching for 'cellular schwannoma'.
Actionable guidance for navigating care for cellular schwannoma
To navigate your care for cellular schwannoma, seek out a specialist in neuro-oncology or a surgeon with experience in treating schwannomas. While there are currently no identified patient organizations, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for additional support. Participation in clinical trials may also be an option; check the active trials listed on ClinicalTrials.gov for opportunities.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.